Press Releases

Date Title and Summary Additional Formats
Toggle Summary Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results
Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $73.0 million for full-year 2019, representing more than 220% growth over 2018 Analysis of Phase 3b trial investigating ZILRETTA in patients with knee OA and synovitis indicates treatment
View HTML
Toggle Summary Flexion Therapeutics Names Melissa Layman Chief Commercial Officer
BURLINGTON, Mass. , March 11, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Melissa Layman has been named Chief Commercial Officer (CCO). Ms. Layman joins Flexion with more than 25 years of commercial experience within the life science industry.
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , March 06, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to three new employees consisting of an aggregate of 8,500 stock options and 1,500 restricted stock units. The Compensation Committee of the Board of Directors
View HTML
Toggle Summary Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2019 Financial Results on March 12, 2020
BURLINGTON, Mass. , March 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth-quarter and full-year 2019 financial results after the close of the U.S. financial markets on Thursday, March 12, 2020 .
View HTML
Toggle Summary Flexion Therapeutics to Present at the 41st Annual Raymond James Institutional Investors Conference
BURLINGTON, Mass. , Feb. 24, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will be presenting at the 41 st  Annual Raymond James Institutional Investors Conference in Orlando, Florida. Michael Clayman, M.D., President and Chief Executive Officer, is
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , Feb. 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to 13 new employees consisting of an aggregate of 40,500 stock options and 6,850 restricted stock units. The Compensation Committee of the Board of Directors
View HTML
Toggle Summary Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2019 Revenue and Initial Revenue Guidance for 2020
Fourth-quarter 2019 revenue estimated to be approximately $23.7 million Full-year 2019 revenue estimated to be approximately $73 million , representing year-over-year growth of more than 220% Flexion provides 2020 product revenue guidance of $120 million to $135 million BURLINGTON, Mass. , Jan.
View HTML
Toggle Summary Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass. , Jan. 03, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to five new employees consisting of an aggregate of 17,000 stock options and 2,800 restricted stock units. The Compensation Committee of the Board of Directors
View HTML
Toggle Summary Flexion Therapeutics Announces FDA Approval of sNDA to Revise ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Product Label
Conference call scheduled for Friday, December 27, 2019 at 8:00 a.m. ET BURLINGTON, Mass. , Dec. 26, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) to update
View HTML
Toggle Summary Flexion Therapeutics Enrolls First Patients in Phase 2 Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in OA of the Shoulder and Adhesive Capsulitis
BURLINGTON, Mass. , Dec. 17, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the first three patients were enrolled in a clinical trial to evaluate the efficacy of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in patients with
View HTML